

Center for Vaccine
Ethics and Policy



Vaccines and Global Health: The Week in Review
13 January 2024 :: Issue 733
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at <https://centerforvaccineethicsandpolicy.net>. This blog allows full text searching of over 27,000 entries.

Comments and suggestions should be directed to

David R. Curry, MS

Editor and

Executive Director

Center for Vaccine Ethics & Policy

david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.*

Support this knowledge-sharing service: *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

:: [Think Tanks](#)

Milestones, Perspectives



WHO – 154th session of the Executive Board

The 154th session of the Executive Board takes place on **22–27 January 2024**. Proceedings will be webcast from [this page](#).

Main Documents page: https://apps.who.int/gb/e/e_eb154.html

Selected Documents

EB154/1

Provisional agenda

EB154/1 (annotated)

Provisional agenda (annotated)

EB154/9

Immunization Agenda 2030

Progress towards global immunization goals and implementation of the Immunization Agenda 2030

EB154/14

WHO's work in health emergencies

Public health emergencies: preparedness and response

EB154/15

WHO's work in health emergencies

Strengthening the global architecture for health emergency preparedness, prevention and response and resilience

EB154/16

Implementation of resolution WHA75.11 (2022)

EB154/18

Poliomyelitis

Poliomyelitis eradication

EB154/19

Poliomyelitis

Polio transition planning and polio post-certification

EB154/20

Smallpox eradication: destruction of variola virus stocks



Gavi Board appoints Senator Dr Sania Nishtar as Chief Executive Officer

- Today, the Board of Gavi, the Vaccine Alliance approved the appointment of Dr Sania Nishtar as its next Chief Executive Officer
- Dr Nishtar, currently a member of the Pakistan Senate, will assume the role on 18 March 2024
- Dr Sania Nishtar: "I am honoured by the trust the Gavi Board placed in me and look forward to working with Gavi's talented staff and skilled Alliance partners."

Geneva, 11 January 2024 – Gavi, the Vaccine Alliance announced today the appointment of Dr Sania Nishtar as its new Chief Executive Officer. Dr Nishtar, currently serving as a Senator in her home country of Pakistan, will assume the role on 18 March 2024.

A trained medical doctor, Dr Nishtar has built an outstanding career over 30 years as a global public health leader. In national government, she served between 2018 and 2022 as Special Assistant to

the Prime Minister on Social Protection and Poverty Alleviation, a role with the status of a Federal Minister. In 2013, during Pakistan’s Caretaker Government, she served as a Federal Minister with responsibility for re-establishing the country’s Ministry of Health among other roles, winning acclaim for transparency and accountability during her time in office.

During her career, Dr Nishtar has fulfilled several leadership positions in civil society and international organisations. She founded the non-profit NGO think tank Heartfile, which campaigns for health reform in Pakistan. She was the inaugural Chair of the UN Secretary-General’s Independent Accountability Panel (IAP) for women’s and children’s health and Co-Chair of the WHO Independent High-level Commission on Noncommunicable Diseases, among many other roles. Dr Nishtar served as Chair of Gavi’s Evaluation Advisory Committee from 2011 to 2014, and in 2016 served as an independent member of Gavi’s Board...

Professor José Manuel Barroso, Chair of the Gavi Board, said: “Over three decades of leadership at the national and global levels, Dr Nishtar has built a reputation as a tireless advocate for health equity, an innovative thinker and a proven doer when it comes to solving complex challenges... I also thank David Marlow for his effective leadership as Gavi’s CEO ad interim. His unfailing commitment to keep Gavi moving forward, by leading important structural and cultural reforms, has ensured Gavi is in the best possible shape to meet its current and future goals.”

Commenting on her appointment, Dr Nishtar said: “Health starts with life-saving vaccines. Over the past 23 years, Gavi has been one of the most impactful organisations in global health. The task ahead is enormous – from health impacts of climate change to the need to tackle vaccine inequity, prepare for future outbreaks and boost routine immunisation, which I believe is the gateway to achieving Universal Health Coverage. I am honoured by the trust the Gavi Board has placed in me and look forward to working with Gavi’s talented staff and skilled Alliance partners to ensure Gavi reaches hundreds of millions of children in lower-income countries with life-saving vaccines against deadly and debilitating diseases.”...

.....
.....

Polio – PHEIC

GPEI press release on nOPV2 prequalification

[WHO grants prequalification to innovative polio vaccine, nOPV2, as nearly 1 billion doses are administered](#)

09/01/2024

In late December 2023, the **World Health Organization issued its first-ever prequalification approval for a vaccine being used under its Emergency Use Listing (EUL) regulatory pathway – novel oral polio vaccine type 2 (nOPV2)**. Since rollout of this next-generation vaccine began in March 2021, the Global Polio Eradication Initiative (GPEI) has administered nearly 1 billion doses of nOPV2 across 35 countries, protecting millions of children against illness and paralysis. Prequalification will enable additional countries to access the vaccine more easily for more sustainable response to outbreaks of type 2 variant poliovirus (cVDPV2).

“This is a historic milestone for polio eradication and for public health,” said WHO Director-General Dr Tedros Adhanom Ghebreyesus. “Novel oral polio vaccine type 2 has blazed a trail for other new vaccines that address critical health emergencies, and its use demonstrates the utility of the EUL mechanism in helping to rapidly get new products to where they’re needed most.”

The EUL to PQ pathway

WHO EUL is reserved for the use of yet-to-be-licensed vaccines, medicines and diagnostic tools during public health emergencies like polio outbreaks. Following rigorous assessments of existing quality, safety and efficacy data from completed clinical trials, the pathway enables expedited availability of products to the places impacted by these emergencies. The vaccine's manufacturer, Bio Farma Indonesia, has been instrumental in ensuring supply and enabling nOPV2 to earn full licensure from the Indonesian regulatory authority, Badan POM. WHO Prequalification (PQ) is the final step of the process, allowing for streamlined regulatory approval for nOPV2 use in countries that need it.

"This key step illustrates how innovation can help protect children against the variant poliovirus type 2, with thanks to the support of donors and partners, and the commitment of governments and community health workers," said UNICEF Executive Director Catherine Russell. "UNICEF is committed to helping ensure the safe and adequate supply of vaccines to countries, while working with communities to build trust in vaccines. We need to keep going till we reach every child, and eradicate polio once and for all."

nOPV2's performance and the power of innovation

To date, nOPV2 has been used in 35 countries under EUL, predominantly in the African region which is most affected by cVDPV2 outbreaks. Throughout its clinical development and field use, nOPV2 has proven to be as safe to use and effective at stopping outbreaks as its predecessor, monovalent type 2 oral vaccine (mOPV2), but, importantly, is more genetically stable. After nearly three years of use, estimates show that nOPV2 is 80% less likely to seed new variant polio outbreaks, making it the tool of choice to stop these outbreaks for good...

To overcome the final challenges that remain in polio eradication, the GPEI is finding new ways to access children living in hard-to-reach areas, promote community acceptance of vaccines, and improve early detection and response to outbreaks. These efforts are being prioritized in the places where children are at the highest risk of encountering and spreading the virus...

A prequalified nOPV2 will help to make important headway against cVDPV2 outbreaks, and with renewed support from global partners, donors and leaders of polio-affected countries to fully implement the program's strategy, we can stop all forms of polio for good.

.....

[Polio this week as of 10 Jan 2024 - GPEI](#)

:: WHO grants prequalification to novel oral polio vaccine type 2 (nOPV2) – the World Health Organization issued its first-ever prequalification approval for a vaccine being used under its Emergency Use Listing (EUL) regulatory pathway – novel oral polio vaccine type 2 (nOPV2). Since rollout of this next-generation vaccine began in March 2021, the Global Polio Eradication Initiative (GPEI) has administered nearly 1 billion doses of nOPV2 across 35 countries, protecting millions of children against illness and paralysis. Prequalification will enable additional countries to access the vaccine more easily for more sustainable response to outbreaks of type 2 variant poliovirus (cVDPV2).

Summary of new polioviruses this week, cases and positive environmental isolates:

- Afghanistan: two wild poliovirus type 1 (WPV1)-positive environmental samples
- Pakistan: 14 WPV1-positive environmental samples
- Guinea: three circulating vaccine-derived poliovirus type 2 (cVDPV2) cases
- Indonesia: one cVDPV2 case and one cVDPV2-positive environmental sample
- Mozambique: one cVDPV2 case
- Nigeria: two cVDPV2 cases

- Tanzania: one cVDPV2-positive environmental sample



Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)



WHO & Regional Offices [to 13 Jan 2024]

<https://www.who.int/news>

Selected News/Announcements/Statements

12 January 2024 News release

[WHO certifies Cabo Verde as malaria-free, marking a historic milestone in the fight against malaria](#)

9 January 2024 Departmental news

[Second WHO global technical consultation on public health and social measures during health emergencies, November 2023](#)



WHO Regional Offices

Selected Press Releases, Announcements

WHO African Region

:: 12 January 2024

[WHO Certifies Cabo Verde as Malaria-Free, Marking a Historic Milestone in the Fight Against Malaria](#)

WHO Region of the Americas PAHO

:: 10 Jan 2024

[Epidemiological Update: Circulation of SARS-CoV-2 and other respiratory viruses in the Americas](#)

Washington, D.C., January 10, 2024 (PAHO) - The Pan American Health Organization (PAHO) this week issued an epidemiological update on respiratory viruses in the Region of the Americas. The update provides recommendations for maintaining surveillance of these viruses and strengthening health systems response, particularly given the current...

WHO South-East Asia Region SEARO

No new digest content identified.

WHO European Region EURO

Website not responding at inquiry.

WHO Eastern Mediterranean Region EMRO

No new digest content identified.

WHO Western Pacific Region

No new digest content identified.

.....

WHO - Emergency situation reports

[Multi-country outbreak of cholera, External situation report #10 - 11 January 2024](#)

Overview

Preliminary data from Member States indicate that the number of cholera cases reported in 2023 as of 15 December has surpassed that of 2022, with over 667 000 cases and 4000 deaths. These figures must be interpreted with caution given the varying surveillance systems and capacity across countries, which means that 2023 data are not directly comparable to reports from previous years.

Since the publication of the last situation report on the multi-country outbreak of cholera on 7 December 2023 (which included data up to 15 November), and as of 15 December 2023, one new country (Togo) has reported an outbreak of cholera or acute watery diarrhoea (AWD). In total, at least 30 countries have reported cases since 1 January 2023.

Nearly a year has passed since WHO classified the global resurgence of cholera as a grade 3 emergency, the highest internal level for a health emergency requiring a comprehensive response at the three levels of the organization. WHO is currently reviewing its response to cholera globally to identify key lessons and make evidence-based adjustments where needed to better coordinate activities in the coming months.

Based on the large number of outbreaks and their geographic expansion, alongside the shortage of vaccines and other resources, WHO continues to assess the risk at global level as very high.

.....

Disease Outbreak News (DONs)

Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.

[11 January 2024 | Circulating vaccine-derived poliovirus type 2 \(cVDPV2\) - Indonesia](#)

On 20 and 27 December 2023, the Indonesian Ministry of Health notified WHO of two confirmed cases of circulating VDPV2.

.....

Weekly Epidemiological Record

<https://www.who.int/publications/journals/weekly-epidemiological-record>

[Vol. 99, No. 01/02, pp. 1–10 12 January 2024](#)

<https://iris.who.int/bitstream/handle/10665/375358/WER9852-eng-fre.pdf>

:: Meningococcal vaccines: WHO position paper on the use of multivalent meningococcal conjugate vaccines

.....

New WHO Publications

<https://www.who.int/publications/i>

Selected

12 January 2024

[Disease outbreak news: annual compendium 2022](#)

12 January 2024

[Meningococcal vaccines: WHO position paper on the use of multivalent meningococcal conjugate vaccines...](#)

12 January 2024

[Global review of the role of artificial intelligence and machine learning in health-care financing for UHC...](#)

12 January 2024

[Global review of the role of artificial intelligence and machine learning in health-care financing for...](#)

9 January 2024

[Scoping the needs and gaps of endemic countries in the onchocerciasis elimination programme: findings...](#)

.....
.....

USA – HHS, FDA, CDC

HHS

News

[Readout of HHS Secretary Becerra’s Meeting with Pharmacies, Pharmacy Benefit Managers, and Insurers on COVID-19 Therapeutics Commercialization](#)

January 9, 2024 News Release

FDA

Press Announcements

No new digest content identified.

FDA VRBPAC

Advisory Committee Calendar

No new meetings scheduled.

CDC/ACIP [U.S.] [to 13 Jan 2024]

<http://www.cdc.gov/media/index.html>

Latest News Releases

No new digest content identified.

ACIP Meetings

Next ACIP Meeting

February 28-29

MMWR Weekly

<https://www.cdc.gov/mmwr/index2023.html>

January 11, 2024 / No. 1

[PDF of this issue](#)

- **Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger – United States, 2024**

- **Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older — United States, 2024**
- **Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing COVID-19–Related Thromboembolic Events Among Medicare Enrollees Aged ≥65 Years and Those with End Stage Renal Disease — United States, September 2022–March 2023**

-

.....

.....

Europe

European Medicines Agency [EMA]

<https://www.ema.europa.eu/en/news>

News & Press Releases

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8-11 January 2024

12 January 2024

...Start of safety review of CAR T-cell medicines

The PRAC started a signal procedure to review data on secondary malignancies related to T-cells (cancers that begin in a type of white blood cells called T-cells), including T-cell lymphoma and leukemia, for the six approved chimeric antigen receptor (CAR) T-cell medicines.

CAR T-cell based gene therapy products belong to a type of personalised cancer immunotherapies where patients' white blood cells (T-cells) are reprogrammed and reinjected to attack the cancer. Six CAR T-cell products are approved in the European Union (EU): Abecma, Breyanzi, Carvykti, Kymriah, Tecartus and Yescarta. These medicines are used to treat blood cancers such as B-cell leukemia, B-cell lymphoma, follicular lymphoma, multiple myeloma and mantle cell lymphoma in patients whose cancer has come back (relapsed) or has stopped responding to previous treatment (refractory).

A secondary malignancy is when a patient who has cancer (current or previous) develops a second cancer different from the first cancer.

For all six CAR T-cell products, secondary malignancies were considered as an important potential risk at the time of their authorisation and included in the Risk Management Plans (RMPs). Close monitoring is already in place and the marketing authorisation holders of the approved medicines are required to regularly submit interim results from the imposed long-term safety and efficacy studies and as part of the Periodic Safety Update Reports (PSURs).

The PRAC is now reviewing all available evidence, including information on 23 cases of various types of T-cell lymphoma or leukemia in EudraVigilance, the EU database of adverse reactions to medicines, and will decide on the need for any regulatory action.

.....

European Centre for Disease Prevention and Control

<https://www.ecdc.europa.eu/en>

News/Updates/Reports/Publications [Selected]

No new digest content identified.

.....

.....

Africa CDC [to 13 Jan 2024]

<http://www.africacdc.org/>

Press Releases, Statements [Selected]

No new digest content identified.

.....
.....

China CDC

<http://www.chinacdc.cn/en/>

National Health Commission of the People's Republic of China [to 13 Jan 2024]

<http://en.nhc.gov.cn/>

News

No new digest content identified.

National Medical Products Administration – PRC [to 13 Jan 2024]

<http://english.nmpa.gov.cn/>

News

No new digest content identified.

China CDC Weekly Reports: Current Volume (6)

2024-01-12 / No. 2

[PDF of this issue](#)

- [Preplanned Studies: Associations Between Air Temperature and Daily Varicella Cases — Jinan City, Shandong Province, China, 2019–2021](#)

.....
.....

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....
.....

Organization Announcements

Paul G. Allen Frontiers Group [to 13 Jan 2024]

<https://alleninstitute.org/news-press/>

News

No new digest content identified.

BMGF - Gates Foundation [to 13 Jan 2024]

<https://www.gatesfoundation.org/ideas/media-center>

Press Releases and Statements

No new digest content identified.

Bill & Melinda Gates Medical Research Institute [to 13 Jan 2024]

<https://www.gatesmri.org/news>

The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people

News: Articles and Publications

No new digest content identified.

CARB-X [to 13 Jan 2024]

<https://carb-x.org/>

News

01.09.2024 |

[Novo Nordisk Foundation partners with CARB-X to fight drug-resistant infections](#)

The Novo Nordisk Foundation is committing up to USD 25 million to support the early-stage development of innovative tools to prevent, diagnose and treat the most dangerous drug-resistant bacterial infections. The three-year grant will go to the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), the leading global non-profit public-private partnership in this space.

CEPI – Coalition for Epidemic Preparedness Innovations [to 13 Jan 2024]

<http://cepi.net/>

Latest News

[The Viral Most Wanted: The Nairovirus Family](#)

The prime suspect in this family is a deadly virus that causes its human victims to bleed profusely

The Viral Most Wanted

11 Jan 2024

CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES [to 13 Jan 2024]

<https://cioms.ch/>

News; Publications; Events

No new digest content identified.

DARPA – Defense Advanced Research Projects Agency [U.S.] [to 13 Jan 2024]

<https://www.darpa.mil/news>

News

No new digest content identified.

Duke Global Health Innovation Center [to 13 Jan 2024]

<https://dukeghic.org/>

News

No new digest content identified.

EDCTP [to 13 Jan 2024]

<http://www.edctp.org/>

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials

News

13 January 2024

[**African women living with HIV have an effective option to prevent malaria during pregnancy**](#)

Emory Vaccine Center [to 13 Jan 2024]

<http://www.vaccines.emory.edu/>

Vaccine Center News

No new digest content identified.

European Vaccine Initiative [to 13 Jan 2024]

<http://www.euvaccine.eu/>

Latest News, Events

No new digest content identified.

Evidence Aid [to 13 Jan 2024]

Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use.

<http://www.evidenceaid.org/>

Resources [Selected]

[**Migration after disasters caused by natural hazards**](#)

Added January 10, 2024

[**Hepatitis B virus among refugees in low- and middle-income countries**](#)

Added January 9, 2024

Fondation Merieux [to 13 Jan 2024]

<http://www.fondation-merieux.org/>

News, Events

No new digest content identified.

Gavi [to 13 Jan 2024]

<https://www.gavi.org/>

News Releases

11 January 2024

[**Gavi Board appoints Senator Dr Sania Nishtar as Chief Executive Officer**](#)

GE2P2 Global Foundation [to 13 Jan 2024]

www.ge2p2.org

News/Analysis/Publications-Digests/Statements

:: [Vaccines and Global Health: The Week in Review](#) - Current edition

:: [Informed Consent: A Monthly Review – January 2024](#)

:: [Genomic Medicine – Governance, Ethics, Policy, Practice: A Monthly Digest](#) – Oct 2023

GHIT Fund [to 13 Jan 2024]

<https://www.ghitfund.org/newsroom/press>

Press Releases

No new digest content identified.

Global Fund [to 13 Jan 2024].

<https://www.theglobalfund.org/en/news/>

News & Stories

No new digest content identified.

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 13 Jan 2024]

<https://www.glopid-r.org/news/>

News

No new digest content identified.

Hilleman Laboratories [to 13 Jan 2024]

<http://www.hilleman-labs.org/>

News & Insights

No new digest content identified.

HHMI - Howard Hughes Medical Institute [to 13 Jan 2024]

<https://www.hhmi.org/news>

Press Room

No new digest content identified.

Human Immunome Project [nee Human Vaccines Project] [to 13 Jan 2024]

<http://www.humanvaccinesproject.org/>

News

No new digest content identified.

IAVI [to 13 Jan 2024]

<https://www.iavi.org/>

News, Features

No new digest content identified.

INSERM [to 13 Jan 2024]

<https://www.inserm.fr/en/home/>

Press Releases

No new digest content identified.

International Coalition of Medicines Regulatory Authorities [ICMRA]

<http://www.icmra.info/drupal/en/news>

Selected Statements, Press Releases, Research

No new digest content identified.

ICH - International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use [to 13 Jan 2024]

<https://www.ich.org/page/press-releases>

News/Pubs/Press Releases [Selective]

No new digest content identified.

ICRC [to 13 Jan 2024]

<https://www.icrc.org/en/whats-new>

What's New [Selected]

[ICRC and Amani Africa Launch a Policy Brief on Safeguarding the Humanitarian Space in Africa: Analysis of Current State of Affairs and Policy Recommendations](#)

Across Africa, a humanitarian crisis unfolds. Spiraling conflicts, a changing climate, and restrictive government policies cast a long shadow on millions in need.

12-01-2024 | Publication

IFFIm

<http://www.iffim.org/>

Press Releases/Announcements

No new digest content identified.

IFRC [to 13 Jan 2024]

<http://media.ifrc.org/ifrc/news/press-releases/>

Press Releases [Selected]

No new digest content identified.

Institut Pasteur [to 13 Jan 2024]

<https://www.pasteur.fr/en/press-area>

Press Documents

Press release

11.01.2024

[Professor Yasmine Belkaid takes office as President of the Institut Pasteur](#)

The Institut Pasteur is pleased to announce that Professor Yasmine Belkaid took office as its new President on January...

ISC / International Science Council [to 13 Jan 2024]

<https://council.science/current/>

ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.

News, Blogs

No new digest content identified.

International Union of Immunological Societies (IUIS)

<https://iuis.org/>

News/Events [Selected]

No new digest content identified.

IVAC [to 13 Jan 2024]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

Updates; Events

No new digest content identified.

IVI [to 13 Jan 2024]

<http://www.ivi.int/>

IVI News & Announcements

No new digest content identified.

Johns Hopkins Center for Health Security [to 13 Jan 2024]

<https://centerforhealthsecurity.org/newsroom>

Center News [Selected]

No new digest content identified.

MSF/Médecins Sans Frontières [to 13 Jan 2024]

<http://www.msf.org/>

Latest [Selected Announcements]

Gaza-Israel war

[**Evacuation orders and bombing around Gaza hospitals leaves people with few healthcare options**](#)

Press Release 12 Jan 2024

National Academy of Medicine - USA [to 13 Jan 2024]

<https://nam.edu/programs/>

News [Selected]

No new digest content identified.

National Academy of Sciences - USA [to 13 Jan 2024]

<https://www.nationalacademies.org/newsroom?>

News

No new digest content identified.

National Vaccine Program Office - U.S. HHS [to 13 Jan 2024]

<https://www.hhs.gov/vaccines/about/index.html>

Upcoming Meetings/Latest Updates

February 22-23, 2024 (Virtual)

NIH [to 13 Jan 2024]

<http://www.nih.gov/>

News Releases

No new digest content identified.

PATH [to 13 Jan 2024]

<https://www.path.org/media-center/>

Newsroom

[The World Health Organization prequalifies novel type 2 oral polio vaccine \(nOPV2\)](#)

Emergency use of nOPV2 has protected millions against polio. Prequalification will ensure broad, long-term accessibility.

Rockefeller Foundation [to 13 Jan 2024]

<https://www.rockefellerfoundation.org/>

Press Releases and Speeches

No new digest content identified.

Sabin Vaccine Institute [to 13 Jan 2024]

<https://www.sabin.org/press/>

Latest News & Press Releases

No new digest content identified.

UNAIDS [to 13 Jan 2024]

<http://www.unaids.org/en>

Selected Press Releases/Reports/Statements

No new digest content identified.

UNICEF [to 13 Jan 2024]

<https://www.unicef.org/media/press-releases>

Latest press releases, news notes and statements

No new digest content identified.

Unitaid [to 13 Jan 2024]

<https://unitaid.org/>

Featured News

No new digest content identified.

Vaccine Equity Cooperative [nee Initiative] [to 13 Jan 2024]

<https://vaccineequitycooperative.org/news/>

News

No new digest content identified.

Vaccination Acceptance & Demand Initiative [Sabin] [to 13 Jan 2024]

<https://www.vaccineacceptance.org/>

Announcements, Blog

No new digest content identified.

Vaccine Confidence Project [to 13 Jan 2024]

<http://www.vaccineconfidence.org/>

News, Research and Reports

No new digest content identified.

Vaccine Education Center – Children’s Hospital of Philadelphia [to 13 Jan 2024]

<http://www.chop.edu/centers-programs/vaccine-education-center>

News

No new digest content identified.

Wellcome Trust [to 13 Jan 2024]

<https://wellcome.org/>

News, Opinion, Reports

No new digest content identified.

The Wistar Institute [to 13 Jan 2024]

<https://www.wistar.org/news/press-releases>

Press Releases

No new digest content identified.

World Bank [to 015 Oct 2022]

<http://www.worldbank.org/en/news/all>

All News [Selected]

No new digest content identified.

WFPHA: World Federation of Public Health Associations [to 13 Jan 2024]

<https://www.wfpha.org/>

No new digest content identified.

World Medical Association [WMA] [to 13 Jan 2024]

<https://www.wma.net/news-press/press-releases/>

Press Releases

Declaration of Helsinki – Phase I Public Comment Period

In order to maximize input by all stakeholders and the public, we are providing two separate public comment periods. A phase 1 public comment period is being held now to address issues from the first few regional meetings, and a phase 2 comment period will follow in the spring when additional topics have been addressed.

Open Now: Phase 1 Public Comment Period Due: 7 February 2024.

The workgroup’s proposed edits to date are now available for public comment. To submit your or your organization’s feedback, download the [phase 1 public comment document](#)

World Organisation for Animal Health [to 13 Jan 2024]

<https://www.oie.int/en/>

Press Releases, Statements

No new digest content identified.

.....

ARM [Alliance for Regenerative Medicine] [to 13 Jan 2024]

<https://alliancerm.org/press-releases/>

Selected Press Releases

No new digest content identified.

BIO [to 13 Jan 2024]

<https://www.bio.org/press-releases>

Press Releases

No new digest content identified.

DCVMN – Developing Country Vaccine Manufacturers Network [to 13 Jan 2024]

<http://www.dcvmn.org/>

News; Upcoming events

No new digest content identified.

ICBA – International Council of Biotechnology Associations [to 13 Jan 2024]

<https://internationalbiotech.org/news/>

News

No new digest content identified.

IFPMA [to 13 Jan 2024]

<https://ifpma.org/>

Selected Press Releases/Statements

No new digest announcements identified

International Alliance of Patients' Organizations – IAPO [to 13 Jan 2024]

<https://www.iapo.org.uk/news>

Press and media [Selected]

No new digest announcements identified

International Generic and Biosimilar Medicines Association [IGBA]

<https://www.igbamedicines.org/>

News

[IGBA announces leadership change \(January 2024\)](#)

The International Generic and Biosimilar Medicines Association (IGBA), representing global manufacturers of generic and biosimilar medicines, announced today that Suzette Kox, the first IGBA Secretary General, has passed on the baton to Dr. Susana Almeida.

PhRMA [to 13 Jan 2024]

<http://www.phrma.org/>

Press Releases

No new digest announcements identified

.....

.....

Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements

AstraZeneca

Press Releases - No new digest announcements identified.

Bharat Biotech

Press Releases - No new digest announcements identified.

BioCubaFarma – Cuba

Últimas Noticias - No new digest announcements identified

Biological E

News - No new digest announcements identified

BioNTech

Press Releases - No new digest announcements identified.

Boehringer

Press Releases - No new digest announcements identified.

CanSinoBIO

News - Website not responding at inquiry

CIGB

Latest News - No new digest announcements identified.

Cinnagen

Recent News - No new digest announcements identified.

Clover Biopharmaceuticals - China

News - No new digest announcements identified.

Curevac [Bayer Ag – Germany]

News - No new digest announcements identified

Gamaleya National Center/Sputnik

Latest News and Events - No new digest announcements identified

<https://sputnikvaccine.com/> - No new digest announcements identified

GSK

Press releases for media - No new digest announcements identified

IMBCAMS, China

Home - Website not responding at inquiry.

Janssen/JNJ

Press Releases - No new digest announcements identified

Merck

News releases - No new digest announcements identified

Moderna

Press Releases - No new digest announcements identified

Nanogen

News - No new digest announcements identified

Novartis

News - No new digest announcements identified.

Novavax

Press Releases - No new digest announcements identified

Pfizer

Recent Press Releases - No new digest announcements identified.

R-Pharm

<https://rpharm-us.com/index.php>

[No news or media page identified]

Sanofi Pasteur

Press Releases - No new digest announcements identified.

Serum Institute of India

NEWS & ANNOUNCEMENTS - No new digest announcements identified

Sinopharm/WIBPBIBP

News - No new digest announcements identified [English translation function not operating]

Sinovac

Press Releases - No new digest announcements identified.

SK Biosciences

Press Releases - No new digest announcements identified.

Takeda

Newsroom - No new digest announcements identified.

Valneva

Press Releases

January 10, 2024

[Valneva Vaccinates First Participant in Pediatric Trial of Single-Shot Chikungunya Vaccine](#)

Vector State Research Centre of Virology and Biotechnology

Home - Website not responding [404 error]

WestVac Biopharma

Media - No new digest announcements identified.

Zhifei Longcom, China

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

Website [No News/Announcements page identified]

.....

.....

Contents [click to move among sections]

:: *Milestones, Perspectives*

:: *WHO*

:: *Organization Announcements*

:: *Journal Watch*

:: *Pre-Print Servers*

.....

.....

Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics

Volume 14, 2023 Issue 4

<https://www.tandfonline.com/toc/uabr21/current>

[Reviewed earlier]

AMA Journal of Ethics

Volume 26, Number 1: E1-96 Jan 2024

<https://journalofethics.ama-assn.org/issue/health-and-loneliness>

Critical Pedagogies in Health Professions Education

Health professions training is mainly competency driven, with students' and trainees' learning and technical skill development regularly assessed, usually in terms of standardized outcomes. Yet, there are good ethical and clinical questions to ask about competency-based medical education, specifically about how schools' and academic health centers' curricula meaningfully motivate learning and skill development about social privilege, health equity, and structural determinants of patients' health and health outcomes. This theme issue considers whether and to what extent skill development about, for example, the affective features of, say, coming to terms with one's privilege is teachable and assessable in competency-based frameworks, especially when those frameworks have a history of excluding key perspectives. Critical pedagogies investigated herein suggest

strategies for interrogating teaching and learning methods and curricular content that are socially, culturally, politically, and historically fraught.

American Journal of Human Genetics

Jan 04, 2024 Volume 111 Issue 1 p1-210

<https://www.cell.com/ajhg/current>

[This Month in The Journal](#)

Alyson B. Barnes, Kylee L. Spencer, Sara B. Cullinan

Biobanks are becoming increasingly common, and although each has its own goals, strengths, and challenges, the standard recipe is a focus on scientific discovery through genetic data linked to electronic health records (EHRs). In this issue, Wiley et al. describe the development of the Colorado Center for Personalized Medicine Biobank (CCPM Biobank), which is not only designed to advance research but also to directly impact patient care. A few key elements were crucial to achieving these dual aims.

[Reviewed earlier]

American Journal of Infection Control

January 2024 Volume 52 Issue 1 p1-140

<http://www.ajicjournal.org/current>

[Reviewed earlier]

American Journal of Preventive Medicine

January 2024 Volume 66 Issue 1 p1-194

<https://www.ajpmonline.org/current>

[Reviewed earlier]

American Journal of Public Health

January 2024 114(1)

<http://ajph.aphapublications.org/toc/ajph/current>

[Reviewed earlier]

American Journal of Tropical Medicine and Hygiene

Volume 110 (2024): Issue 1 (Jan 2024)

<https://www.ajtmh.org/view/journals/tpmd/110/1/tpmd.110.issue-1.xml>

[Reviewed earlier]

Annals of Internal Medicine

December 2023 Volume 176, Issue 12

<https://www.acpjournals.org/toc/aim/current>

[Reviewed earlier]

Artificial Intelligence – An International Journal

Volume 327 February 2024

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/327/suppl/C>

[New issue; No digest content identified]

BMC Cost Effectiveness and Resource Allocation

<http://resource-allocation.biomedcentral.com/>

(Accessed 13 Jan 2024)

[No new digest content identified]

BMC Health Services Research

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 13 Jan 2024)

[No new digest content identified]

BMC Infectious Diseases

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 13 Jan 2024)

[No new digest content identified]

BMC Medical Ethics

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 13 Jan 2024)

[No new digest content identified]

BMC Medicine

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 13 Jan 2024)

[Evolution in key indicators of maternal and child health across the wealth gradient in 41 sub-Saharan African countries, 1986–2019](#)

Aggregate trends can be useful for summarizing large amounts of information, but this can obscure important distributional aspects. Some population subgroups can be worse off even as averages climb, for exampl...

Authors: Yeeun Lee, Sarah Bolongaita, Ryoko Sato, Jesse B. Bump and Stéphane Verguet

Citation: BMC Medicine 2024 22:21

Content type: Research article Published on: 8 January 2024

BMC Pregnancy and Childbirth

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 13 Jan 2024)

[No new digest content identified]

BMC Public Health

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 13 Jan 2024)

[Immunisation coverage and factors associated with incomplete immunisation in children under two during the COVID-19 pandemic in Sierra Leone](#)

Routine childhood immunisation is one of the most important life-saving public health interventions. However, many children still have inadequate access to these vaccines and millions remain (partially) unvacc...

Authors: Myrte Wassenaar, Augustin E. Fombah, Haily Chen, Kwabena Owusu-Kyei, Julian Williams, Joe-Henry C. Saunders, Mireia Llach, Llorenç Quinto, Tom Sesay, Mohamed Samai, Clara Menéndez and Raquel González

Citation: BMC Public Health 2024 24:143

Content type: Research Published on: 10 January 2024

BMC Research Notes

<http://www.biomedcentral.com/bmcresnotes/content>

(Accessed 13 Jan 2024)

[No new digest content identified]

BMJ Evidence-Based Medicine

December 2023 - Volume 28 - 6

<https://ebm.bmj.com/content/28/6>

[Reviewed earlier]

BMJ Global Health

January 2024 - Volume 9 - 1

<https://gh.bmj.com/content/9/1>

[Reviewed earlier]

Bulletin of the Atomic Scientists

November 2023

<https://thebulletin.org/magazine/2023-11/>

[Reviewed earlier]

Bulletin of the World Health Organization

Volume 102(1); 2024 Jan 1

<https://www.ncbi.nlm.nih.gov/pmc/issues/451803/>

[Reviewed earlier]

Cell

Jan 04, 2024 Volume 187 Issue 1 p1-216

<https://www.cell.com/cell/current>

[Reviewed earlier]

Child Care, Health and Development

Volume 50, Issue 1 January 2024

<https://onlinelibrary.wiley.com/toc/13652214/current>

[New issue; No digest content identified]

Clinical Pharmacology & Therapeutics

Volume 115, Issue 1 Pages: 1-157 January 2024

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

[Reviewed earlier]

Clinical Therapeutics

January 2024 Volume 46 Issue 1 p1-84

<http://www.clinicaltherapeutics.com/current>

[Reviewed earlier]

Clinical Trials

Volume 20 Issue 6, December 2023

<https://journals.sagepub.com/toc/ctja/20/6>

[Reviewed earlier]

Conflict and Health

<http://www.conflictandhealth.com/>

[Accessed 13 Jan 2024]

[Health systems resilience in fragile and conflict-affected settings: a systematic scoping review](#)

Health systems resilience (HSR) research is a rapidly expanding field, in which key concepts are discussed and theoretical frameworks are emerging with vibrant debate. Fragile and conflict-affected settings (F...

Authors: Claudia Truppa, Sally Yaacoub, Martina Valente, Giulia Celentano, Luca Ragazzoni and Dell Saulnier

Citation: Conflict and Health 2024 18:2

Content type: Research Published on: 3 January 2024

Contemporary Clinical Trials

Volume 135 December 2023

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/135/suppl/C>

[New issue; No digest content identified]

The CRISPR Journal

Volume 6, Issue 6 / December 2023

<https://www.liebertpub.com/toc/crispr/6/6>

[Reviewed earlier]

Current Genetic Medicine Reports

Volume 11, issue 1-2, June 2023

<https://link.springer.com/journal/40142/volumes-and-issues/11-1>

[Reviewed earlier]

Current Medical Research and Opinion

Volume 40, Issue 1 2024

<https://www.tandfonline.com/toc/icmo20/current>

[Reviewed earlier]

Current Opinion in Infectious Diseases

February 2024 - Volume 37 - Issue 1

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

[Reviewed earlier]

Current Protocols in Human Genetics

<https://currentprotocols.onlinelibrary.wiley.com/journal/19348258>

[Accessed 13 Jan 2024]

[No new digest content identified]

Developing World Bioethics

Volume 23, Issue 4 Pages: 293-377 December 2023

<https://onlinelibrary.wiley.com/toc/14718847/current>

ORIGINAL ARTICLES

[Reviewed earlier]

Development in Practice

Volume 33, Issue 8, 2023

<http://www.tandfonline.com/toc/cdip20/current>

[Reviewed earlier]

Development Policy Review

Volume 42, Issue 1 January 2024

<https://onlinelibrary.wiley.com/toc/14677679/current>

[Reviewed earlier]

Disaster Medicine and Public Health Preparedness

Volume 17 - 2024

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[Reviewed earlier]

Disasters

Volume 47, Issue 4 Pages: 847-1173 October 2023

<https://onlinelibrary.wiley.com/toc/14677717/2023/47/4>

[Reviewed earlier]

EMBO Reports

Volume 24 Issue 12 6 December 2023

<https://www.embopress.org/toc/14693178/current>

[Reviewed earlier]

Emerging Infectious Diseases

Volume 29, Number 12—December 2023

<http://wwwnc.cdc.gov/eid/>

[New issue; No digest content identified]

Epidemics

Volume 45 December 2023

<https://www.sciencedirect.com/journal/epidemics/vol/45/suppl/C>

[Reviewed earlier]

Epidemiology and Infection

Volume 152 - 2024

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[Reviewed earlier]

Ethics & Human Research

Volume 45, Issue 6 Pages: 1-50 November–December 2023

<https://onlinelibrary.wiley.com/toc/25782363/current>

Passing demands in autism research :: Women missing in phase I trials

[Reviewed earlier]

Ethics & International Affairs

Volume 37 - Issue 3 - Fall 2023

<https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue>

[Reviewed earlier]

Ethics, Medicine and Public Health

Volume 31 (December 2023)

<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/31/suppl/C>

[Reviewed earlier]

The European Journal of Public Health

Volume 33, Issue 6, December 2023

<https://academic.oup.com/eurpub/issue/33/6>

[Reviewed earlier]

Expert Review of Vaccines

Vol 22 (1) 2023

<https://www.tandfonline.com/toc/ierv20/current>

[Reviewed earlier]

Foreign Affairs

January/February 2024 Volume 103, Number 1
<https://www.foreignaffairs.com/issues/2023/103/1>
[Reviewed earlier]

Forum for Development Studies

Volume 50, 2023 - Issue 3
<http://www.tandfonline.com/toc/sfds20/current>
[Reviewed earlier]

Genetics in Medicines

Volume 26, Issue 1 January 2024
<https://www.sciencedirect.com/journal/genetics-in-medicine/vol/25/issue/12>
[Reviewed earlier]

Genome Medicine

<https://genomemedicine.biomedcentral.com/articles>
[Accessed 13 Jan 2024]
[No new digest content identified]

Global Health Action

Volume 17, Issue 1 (2024)
<https://www.tandfonline.com/toc/zgha20/current?nav=toCList>
[Reviewed earlier]

Global Health: Science and Practice (GHSP)

Vol. 11, No. 6 December 22, 2023
<http://www.ghspjournal.org/content/current>
[Reviewed earlier]

Global Legal Monitor & Legal Reports – Library of Congress/USA

<https://www.loc.gov/collections/global-legal-monitor/>
https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date_desc
[Accessed 13 Jan 2024]
[No new digest content identified]

Global Public Health

Volume 19, Issue 1 (2024)
<http://www.tandfonline.com/toc/rqph20/current>
[Reviewed earlier]

Globalization and Health

<http://www.globalizationandhealth.com/>
[Accessed 13 Jan 2024]

[No new digest content identified]

Health and Human Rights

Volume 25, Issue 2, December 2023

<https://www.hhrjournal.org/volume-25-issue-2-december-2023/>

Special Section: Economic Inequality and the Right to Health

Health Economics, Policy and Law

Volume 18 - Special Issue 4 - October 2023

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

SPECIAL ISSUE: On the roof top of health policy change

[Reviewed earlier]

Health Policy and Planning

Volume 38, Issue 10, December 2023

<https://academic.oup.com/heapol/issue/38/10>

[Reviewed earlier]

Health Research Policy and Systems

<http://www.health-policy-systems.com/content>

[Accessed 13 Jan 2024]

[No new digest content identified]

Human Gene Therapy

Volume 34, Issue 23-24 / December 2023

<https://www.liebertpub.com/toc/hum/34/23-24>

[No new digest content identified]

Humanitarian Practice Network

<https://odihpn.org/>

Featured Publications

[No new digest content identified]

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)

Volume 19, Issue 3, 2023

<https://www.tandfonline.com/toc/khvi20/19/3?nav=tocList>

[Reviewed earlier]

Immunity

Dec 12, 2023 Volume 56 Issue 12 p2665-2856

<https://www.cell.com/immunity/current>

[Reviewed earlier]

Infectious Agents and Cancer

<http://www.infectagentscancer.com/>

[Accessed 13 Jan 2024]

[No new digest content identified]

Infectious Diseases of Poverty

<http://www.idpjournals.com/content>

[Accessed 13 Jan 2024]

[No new digest content identified]

International Health

Volume 15, Issue 6, November 2023

<https://academic.oup.com/inthealth/issue/15/6>

[Reviewed earlier]

International Human Rights Law Review

Volume 12 (2023): Issue 2 (Dec 2023)

<https://brill.com/view/journals/hrlr/12/2/hrlr.12.issue-1.xml>

Table of Contents

[New issue; No digest content identified]

International Journal of Community Medicine and Public Health

Vol. 10 No. 9 (2023): September 2023

<https://www.ijcmph.com/index.php/ijcmph/issue/view/104>

[Reviewed earlier]

International Journal of Epidemiology

Volume 52, Issue 6, December 2023

<https://academic.oup.com/ije/issue>

[Reviewed earlier]

International Journal of Human Rights in Healthcare

Volume 16 Issue 3 2023

<https://www.emerald.com/insight/publication/issn/2056-4902/vol/16/iss/3>

Table of contents

[Reviewed earlier]

JAMA

January 9, 2024, Vol 331, No. 2, Pages 93-176

<https://jamanetwork.com/journals/jama/currentissue>

[New issue; No digest content identified]

JAMA Health Forum

January 2024, Vol 5, No. 1

<https://jamanetwork.com/journals/jama-health-forum/issue>

[Reviewed earlier]

JAMA Pediatrics

January 2024, Vol 5, No. 1

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

[Reviewed earlier]

JBIE Evidence Synthesis

December 2023 - Volume 21 - Issue 12

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[Reviewed earlier]

Journal of Adolescent Health

January 2024 Volume 74 Issue 1 p1-212

<https://www.jahonline.org/current>

[Reviewed earlier]

Journal of Artificial Intelligence Research

Vol. 78 (2023)

<https://www.jair.org/index.php/jair>

Contents

[Reviewed earlier]

Journal of Community Health

Volume 48, issue 6, December 2023

<https://link.springer.com/journal/10900/volumes-and-issues/48-6>

[Reviewed earlier]

Journal of Current Medical Research and Opinion

...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged.

Vol. 7 No. 01 (2024), January 2, 2024 , Page 1988-1996

<https://www.cmro.in/index.php/jcmro/issue/view/75>

[New issue; No digest content identified]

Journal of Development Economics

Volume 166 January 2024

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/166/suppl/C>

[Reviewed earlier]

Journal of Empirical Research on Human Research Ethics

Volume 18 Issue 5, December 2023

<http://journals.sagepub.com/toc/jre/current>

[Reviewed earlier]

Journal of Epidemiology & Community Health

January 2024 - Volume 78 - 1

<https://jech.bmj.com/content/78/1>

[Reviewed earlier]

Journal of Evidence-Based Medicine

Volume 16, Issue 4 Pages: 415-580 December 2023

<https://onlinelibrary.wiley.com/toc/17565391/current>

[Reviewed earlier]

Journal of Global Ethics

Volume 19, Issue 2 (2023)

<http://www.tandfonline.com/toc/rjge20/current>

[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)

Volume 34, Number 4, November 2023

<https://muse.jhu.edu/issue/51329>

Table of Contents

[Reviewed earlier]

Journal of Immigrant and Minority Health

Volume 25, issue 6, December 2023

<https://link.springer.com/journal/10903/volumes-and-issues/25-6>

[Reviewed earlier]

Journal of Immigrant & Refugee Studies

Volume 21, 2023 _ Issue 4

<https://www.tandfonline.com/toc/wimm20/current>

Towards a New Migration and Asylum Research Agenda for the Americas

Journal of Infectious Diseases

Volume 228, Issue 12, 15 December 2023

<https://academic.oup.com/jid/issue/228/12>

[New issue; No digest content identified]

Journal of International Development

Volume 35, Issue 8 Pages: 2251-2685 November 2023

<https://onlinelibrary.wiley.com/toc/10991328/current>

[Reviewed earlier]

Journal of Medical Ethics

January 2024 - Volume 50 - 1

<http://jme.bmj.com/content/current>

[New issue; No digest content identified]

Journal of Patient-Centered Research and Reviews

Volume 10, Issue 4 (2023)

<https://institutionalrepository.aah.org/jpcrr/>

[New issue; No digest content identified]

The Journal of Pediatrics

Volume 264 January 2024

<https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/264/suppl/C>

[Reviewed earlier]

Journal of Pharmaceutical Policy and Practice

<https://joppp.biomedcentral.com/>

[Accessed 13 Jan 2024]

[No new digest content identified]

Journal of Public Health Management & Practice

January/February 2024 - Volume 30 - Issue 1

<https://journals.lww.com/jphmp/pages/currenttoc.aspx>

[Reviewed earlier]

Journal of Public Health Policy

Volume 44, issue 4, December 2023

<https://link.springer.com/journal/41271/volumes-and-issues/44-4>

[New issue; No digest content identified]

Journal of the Royal Society – Interface

January 2024 Volume 21 Issue 210

<https://royalsocietypublishing.org/toc/rsif/current>

[Reviewed earlier]

Journal of Travel Medicine

Volume 30, Issue 8, December 2023

<https://academic.oup.com/jtm/issue>

[Reviewed earlier]

Journal of Virology

Volume 97 • Number 12 • December 2023

<http://jvi.asm.org/content/current>

[New issue; No digest content identified]

The Lancet

Jan 13, 2024 Volume 403 Number 10422 p117-218, e2-e6

<https://www.thelancet.com/journals/lancet/issue/current>

Comment

[The future of the global clinical trial ecosystem: a vision from the first WHO Global Clinical Trials Forum](#)

Vasee Moorthy...Jeremy Farrar

The first WHO Global Clinical Trials Forum 1 held at WHO, Geneva, Switzerland, on Nov 20–21, 2023, brought together a diverse community to advance sustainable global clinical trial infrastructure. To secure the improvements needed to “strengthen clinical trials”, as mandated by the World Health Assembly in May, 2022, 2 the Forum agreed a unified vision of “always on, always busy”, whereby sustained national and global clinical trial capacity during and between crises ensures clinical research and trials are integrated and sustained in all health systems so that trials can help improve health outcomes for all, all the time.

[Moving cholera vaccines ahead of the epidemic curve](#)

Ziad A Memish, et al

The ongoing multi-country cholera outbreaks deserve greater attention and higher prioritisation globally. 1 Since the early 1800s, there have been seven characterised global outbreaks of cholera. The seventh and current pandemic has been causing considerable illness effects since the early 1960s. 2 Most recently, floods, droughts, natural disasters, and conflicts have displaced millions of people who have restricted access to clean water and live in settings with poor sewage management and increasing disease risk, further increasing the devastating effect of cholera around the globe. 3 Currently, 1 billion people are at risk of contracting cholera and, concerningly, 28 countries with outbreaks in 2023, and 24 countries with active outbreaks were recorded by WHO by Sept 10, 2023 alone. 4 In addition, recent outbreaks have had a high case fatality rate. 5 The average cholera case fatality rate reported globally in 2021 was 1·9% (2·9% in Africa), a significant increase above the accepted target rate (<1%) and the highest recorded in over a decade. 1 , 5 Preliminary data suggest a similar trend for 2022 and 2023. 1 Cholera is an old adversary that is both preventable and treatable. 5 Despite widespread calls for strengthened pandemic preparedness and response, the global public health community are failing to apply lessons learned from COVID-19 to old challenges such as cholera. A key lesson learned from the COVID-19 pandemic is that early, rapid, and aggressive action is crucial in implementing public health interventions and countermeasure development. 6

The Lancet Child & Adolescent Health

Jan 2024 Volume 8 Number 1 p1-84

<https://www.thelancet.com/journals/lanchi/issue/current>

[Reviewed earlier]

Lancet Digital Health

Dec 2023 Volume 5 Number 12 e848-e932

<https://www.thelancet.com/journals/landig/issue/current>

[Reviewed earlier]

Lancet Global Health

Jan 2024 Volume 12 Number 1 e1-e169
<https://www.thelancet.com/journals/langlo/issue/current>
[Reviewed earlier]

Lancet Infectious Diseases

Jan 2024 Volume 24 Number 1 p1-106, e1-e69
<https://www.thelancet.com/journals/laninf/issue/current>
[Reviewed earlier]

Lancet Public Health

Jan 2024 Volume 9 Number 1 e1-e67
<https://www.thelancet.com/journals/lanpub/issue/current>
[New issue; No digest content identified]

Lancet Respiratory Medicine

Jan 2024 Volume 12 Number 1 p1-88
<https://www.thelancet.com/journals/lanres/issue/current>
[Reviewed earlier]

Maternal and Child Health Journal

Volume 27, issue 12, December 2023
<https://link.springer.com/journal/10995/volumes-and-issues/27-12>
[Reviewed earlier]

Medical Decision Making (MDM)

Volume 101, Issue 4 Pages: 999-1374 December 2023
<http://mdm.sagepub.com/content/current>
[Reviewed earlier]

The Milbank Quarterly

A Multidisciplinary Journal of Population Health and Health Policy
Volume 101, Issue 3 Pages: 637-998 September 2023
<https://onlinelibrary.wiley.com/toc/14680009/current>
[Reviewed earlier]

Molecular Therapy

Jan 03, 2024 Volume 32 Issue 1 p1-260
<https://www.cell.com/molecular-therapy/current>
[Reviewed earlier]

Nature

Volume 625 Issue 7994, 11 January 2024
<https://www.nature.com/nature/volumes/625/issues/7994>
[New issue; No digest content identified]

Nature Biotechnology

Volume 41 Issue 12, December 2023

<https://www.nature.com/nbt/volumes/41/issues/12>

[Reviewed earlier]

Nature Communications

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 13 Jan 2024)

[No new digest content identified]

Nature Genetics

Volume 56 Issue 1, January 2024

<https://www.nature.com/ng/volumes/56/issues/1>

Editorial 02 Jan 2024

[A call for spatial omics submissions](#)

The field of spatial omics is developing rapidly, with a potentially transformative effect across many areas of biology. Nature Genetics invites authors to submit papers that use these techniques to answer questions of broad interest to researchers working in genetics and genomics.

Nature Human Behaviour

Volume 7 Issue 12, December 2023

<https://www.nature.com/nathumbehav/volumes/7/issues/12>

Moral reasoning in the brain

[Reviewed earlier]

Nature Medicine

Volume 29 Issue 12, December 2023

<https://www.nature.com/nm/volumes/29/issues/12>

[Reviewed earlier]

Nature Reviews Drug Discovery

Volume 22 Issue 11, November 2023

<https://www.nature.com/nrd/volumes/22/issues/11>

[Reviewed earlier]

Nature Reviews Genetics

Volume 25 Issue 1, January 2024

<https://www.nature.com/nrg/volumes/25/issues/1>

[Reviewed earlier]

Nature Reviews Immunology

Volume 23 Issue 12, December 2023

<https://www.nature.com/nri/volumes/23/issues/12>

[Reviewed earlier]

New England Journal of Medicine

January 11, 2024 Vol. 390 No. 2

<https://www.nejm.org/toc/nejm/medical-journal>

[New issue; No digest content identified]

njp Vaccines

<https://www.nature.com/njpvaccines/>

[Accessed 13 Jan 2024]

[No new digest content identified]

Pediatrics

Volume 153, Issue 1 January 2024

<https://publications.aap.org/pediatrics/issue/152/4>

[Reviewed earlier]

PharmacoEconomics

Volume 41, Issue 12 December 2023

<https://link.springer.com/journal/40273/volumes-and-issues/41-12>

[Reviewed earlier]

PLoS Biology

<https://journals.plos.org/plosbiology/>

(Accessed 13 Jan 2024)

[No new digest content identified]

PLoS Genetics

<https://journals.plos.org/plosgenetics/>

(Accessed 13 Jan 2024)

[No new digest content identified]

PLoS Global Public Health

https://journals.plos.org/globalpublichealth/search?sortOrder=DATE_NEWEST_FIRST&filterStartDate=2021-10-01&filterJournals=PLOGlobalPublicHealth&q=&resultsPerPage=60

(Accessed 13 Jan 2024)

[Global health in the age of AI: Safeguarding humanity through collaboration and action](#)

Carlos A. Faerron Guzmán

Opinion | published 11 Jan 2024 PLOS Global Public Health

<https://doi.org/10.1371/journal.pgph.0002778>

Abstract

This opinion article discusses the impact of artificial intelligence (AI) on global health, addressing its potential risks and benefits to the field. It suggests that, given the existential risks of AI development, the global health community must contribute to AI-related advances, ensuring health equity and the wellbeing of vulnerable populations. Through transdisciplinary collaborations, robust

AI governance, and an emphasis on equity, strategies are proposed to harness the potential of AI to reduce health inequalities and improve wellbeing at global and local levels.

[User-experience testing of an evidence-to-decision framework for selecting essential medicines](#)

Thomas Piggott, Lorenzo Moja, Carlos A. Cuello Garcia, Elie A. Akl, Rita Banzi, Benedikt Huttner, Tamara Kredon, John N. Lavis, Holger J. Schünemann

Research Article | published 11 Jan 2024 PLOS Global Public Health

<https://doi.org/10.1371/journal.pgph.0002723>

PLoS Medicine

<http://www.plosmedicine.org/>

(Accessed 13 Jan 2024)

[No new digest content identified]

PLoS Neglected Tropical Diseases

<http://www.plosntds.org/>

(Accessed 13 Jan 2024)

[No new digest content identified]

PLoS One

<http://www.plosone.org/>

[Accessed 13 Jan 2024]

[No new digest content identified]

PLoS Pathogens

<http://journals.plos.org/plospathogens/>

[Accessed 13 Jan 2024]

[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States

January 16, 2024 | vol. 121 | no. 3

<https://www.pnas.org/toc/pnas/121/3>

[New issue; No digest content identified]

PNAS Nexus

Volume 2, Issue 12, December 2023

<https://academic.oup.com/pnasnexus/issue/2/12>

[Reviewed earlier]

Prehospital & Disaster Medicine

Volume 38 - Issue 6 - December 2023

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[Reviewed earlier]

Preventive Medicine

Volume 178 January 2024

<https://www.sciencedirect.com/journal/preventive-medicine/vol/178/suppl/C>

[Reviewed earlier]

Proceedings of the Royal Society B

10 January 2024 Volume 291 Issue 2014

<https://royalsocietypublishing.org/toc/rspb/current>

[Reviewed earlier]

Public Health

Volume 225 Pages e1-e4, 1-376 (December 2023)

<https://www.sciencedirect.com/journal/public-health/vol/225/suppl/C>

[Reviewed earlier]

Public Health Ethics

Volume 16, Issue 2, July 2023

<http://phe.oxfordjournals.org/content/current>

[Reviewed earlier]

Public Health Genomics

2023, Vol. 26, No. 1

<https://karger.com/phg/issue/26/1>

[Reviewed earlier]

Public Health Reports

Volume 139 Issue 1, January/February 2024

<https://journals.sagepub.com/toc/phrg/139/1>

[Reviewed earlier]

Qualitative Health Research

Volume 34 Issue 3, February 2024

<https://journals.sagepub.com/toc/QHR/current>

[Reviewed earlier]

Research Ethics

Volume 20 Issue 1, January 2024

<http://journals.sagepub.com/toc/reab/current>

Open Access Research article First published September 8, 2023pp. 79–95

[**Researchers' responsibilities in resource-constrained settings: experiences of implementing an ancillary care policy in a vaccine trial in the Democratic Republic of the Congo**](#)

Gwen Lemey, et al.

Reproductive Health

<http://www.reproductive-health-journal.com/content>

[Accessed 13 Jan 2024]

[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)

<https://www.paho.org/journal/en>

19 Dec 2023

[Developing and sustaining high-quality care for children with cancer: the WHO Global Initiative for Childhood Cancer](#)

Opinion and analysis | English |

18 Dec 2023

[Evaluating elimination of mother-to-child transmission of HIV in Suriname: a mixed method study](#)

Original research | English |

Risk Analysis

Volume 44, Issue 1 Pages: 1-280 January 2024

<https://onlinelibrary.wiley.com/toc/15396924/current>

[Reviewed earlier]

Risk Management and Healthcare Policy

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 13 Jan 2024]

[Reviewed earlier]

Science

Volume 383| Issue 6679|12 Jan 2024

<https://www.science.org/toc/science/current>

Editorial

[Rooting out scientific misconduct](#)

BY Ivan Oransky, Barbara Redman

11 Jan 2024

Science and Engineering Ethics

Volume 29, Issue 6 December 2023

<https://link.springer.com/journal/11948/volumes-and-issues/29-6>

[Reviewed earlier]

Science Translational Medicine

Volume 16| Issue 729| 10 Jan 2024

<https://www.science.org/toc/stm/current>

Reviews

[Prospective study design and data analysis in UK Biobank](#)

BY Naomi E. Allen [...] Rory Collins

10 Jan 2024

The study design, resource access, and data analysis of UK Biobank is facilitating health-related research worldwide.

Scientific Reports

<https://www.nature.com/srep/articles?type=article>

[Accessed 13 Jan 2024]

[No new digest content identified]

Social Science & Medicine

Volume 339 December 2023

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/339/suppl/C>

[Reviewed earlier]

Systematic Reviews

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 13 Jan 2024]

[No new digest content identified]

Theoretical Medicine and Bioethics

Volume 44, Issue 6 December 2023

<https://link.springer.com/journal/11017/volumes-and-issues/44-6>

[Reviewed earlier]

Travel Medicine and Infectious Diseases

Volume 56 November–December 2023

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/56/suppl/C>

[Reviewed earlier]

Tropical Medicine & International Health

Volume 29, Issue 1 Pages: i-iv, 1-71 January 2024

<https://onlinelibrary.wiley.com/toc/13653156/current>

[Reviewed earlier]

Vaccine

Volume 42, Issue 2 Pages 65-402 (12 January 2024)

<https://www.sciencedirect.com/journal/vaccine/vol/42/issue/2>

[Reviewed earlier]

Vaccines

<https://www.mdpi.com/journal/vaccines>

[Accessed 13 Jan 2024]

Latest Articles [Selected]

Open Access Article

[Determinants of Human Papillomavirus Vaccine Acceptance among Caregivers in Nigeria: A Fogg Behavior Model-Based Approach](#)

by [Sohail Agha](#), et al.

Vaccines 2024, 12(1), 84; <https://doi.org/10.3390/vaccines12010084> (registering DOI) - 13 Jan 2024

Abstract

Human papillomavirus (HPV) vaccine uptake among adolescent girls is critical to reducing the burden of HPV-related cancers in Nigeria. This study assesses the factors influencing caregivers' acceptance of HPV vaccination for their charges, using the Fogg Behavior Model (FBM) as a theoretical framework.

Value in Health

January 2024 Volume 27 Issue 1 p1-132

[New issue; No digest content identified]

World Development

Volume 175 March 2024

<https://www.sciencedirect.com/journal/world-development/vol/175/suppl/C>

[Reviewed earlier]

.....

.....

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....

.....

Pre-Print Servers

Gates Open Research

<https://gatesopenresearch.org/browse/articles>

[Accessed 13 Jan 2024]

Selected Research

Method Article

[Estimating dengue disease and economic burden to inform municipal-level policymakers: Method for a pragmatic city-level observational cohort study](#)

[version 1; peer review: awaiting peer review]

Nandy N. Wilastonegoro¹, Sri Andriani², Perigrinus H. Sebong³, Priya Agarwal-Harding⁴, Donald S. Shepard

Abstract

Background

Recent trials have confirmed the effectiveness of promising dengue control technologies – two vaccines, and Wolbachia. These would generally be applied at the municipal level. To balance health

needs and resource constraints, local officials need affordable, timely, and accurate data. Building on our previous work in Mexico, Indonesia, and Thailand, we developed a streamlined prospective method to estimate dengue burden at the municipal level quickly, accurately, and efficiently.

medRxiv

<https://www.medrxiv.org/content/about-medrxiv>

[Accessed 13 Jan 2024]

[Filter: All articles]

[Estimated number of lives directly saved by COVID-19 vaccination programs in the WHO European Region, December 2020 to March 2023](#)

Margaux MI Mesle, Jeremy Brown, Piers Mook, Mark A Katz, Jose Hagan, Roberta Pastore, Dorit Nitzan, Bernhard Benka, Monika Redlberger-Fritz, Nathalie Bossuyt, Veerle Stouten, Catharina Vernemmen, Elisabet Constantinou, Jan Kyncl, Marek Maly, Ondrej Sanca, Tyra Grove Krause, Lasse Skafte Vestergaard, Tuija Leino, Eero Poukka, Kassiani Gkolfinopoulou, Kassiani Mellou, Maria Maria Tsintziloni, Zsuzsanna Molnar, Gudrun Aspelund, Marianna Thordardottir, Lisa Domegan, Eva Kelly, Joan O'Donell, Chiara Sacco, Flavia Riccardo, Alberto Mateo Urdiales, Viktoras Bumsteinas, Rasa Liausediene, Joel Mossong, Anne Vergison, Maria-Louise Borg, Tanya Melillo, Dragan Kocinski, Enkela Pollozhani, Hinta Meijerink, Diana Costa, Joao Paulo Gomes, Pedro Pinto Leite, Alina Druc, Veaceslav Gutu, Valentin Mita, Mihaela Lazar, Rodica Popescu, Odette Popovici, Monika Musilova, Maja Mrzel, Maja Socan, Veronika Ucar, Aurora Limia, Clara Mazagatos, Carmen Olmedo, Gavin Dabrera, Megan Kall, Mary Sinnathamby, Jim McMenamain, Graham McGowan, Kirsty Morrison, Marc-Alain Widdowson, Catherine Smallwood, Richard Pebody

medRxiv 2024.01.12.24301206; doi: <https://doi.org/10.1101/2024.01.12.24301206>

Abstract

Background: By March 2023, 54 countries, areas and territories (thereafter "CAT") reported over 2.2 million coronavirus disease 2019 (COVID-19) deaths to the World Health Organization (WHO) Regional Office for Europe (1). Here, we estimate how many lives were directly saved by vaccinating adults in the Region, from December 2020 through March 2023. Methods: We estimated the number of lives directly saved by age-group, vaccine dose and circulating Variant of Concern (VOC) period, both regionally and nationally, using weekly data on COVID-19 mortality and COVID-19 vaccine uptake reported by 34 CAT, and vaccine effectiveness (VE) data from the literature. We calculated the percentage reduction in the number of expected and reported deaths. Findings: We found that vaccines reduced deaths by 57% overall (CAT range: 15% to 75%), representing ~1.4 million lives saved in those aged ≥ 25 years (range: 0.7 million to 2.6 million): 96% of lives saved were aged ≥ 60 years and 52% were aged ≥ 80 years; first boosters saved 51%, and 67% were saved during the Omicron period. Interpretation: Over nearly 2.5 years, most lives saved by COVID-19 vaccination were in older adults by first booster dose and during the Omicron period, reinforcing the importance of up-to-date vaccination among these most at-risk individuals. Further modelling work should evaluate indirect effects of vaccination and public health and social measures.

[Factors that influence-COVID-19 Vaccine Uptake and Hesitancy Among a Population in the West Department of Haiti: Implications for Enhancing Effectiveness of Immunization Programs](#)

Martine Etienne-Mesubi, Babatunji Oni, Nancy Rachel Labbe-Coq, Marie Colette Alcide-Jean-Pierre, Delva Lamarre, Darwin Dorestan, Marie-Ange Bien-Aime, Venice Dorce, Cory Freivald, Cowan Angell, Yingjie Wang, Jenevieve Opoku, Bryan Shaw, Deus Bazira

medRxiv 2024.01.10.24301096; doi: <https://doi.org/10.1101/2024.01.10.24301096>

[The landscape of paediatric infectious disease exposure in a rural sub-Saharan Africa setting in Kilifi, Kenya: longitudinal serological analysis over two decades and priorities for future vaccine development](#)

Deirdre F Foley, Timothy K Chege, Joyce Kabagenyi, Karen McCarthy, Elijah T Gicheru, Nelson Kibinge, Angela W Maina, Jacqueline M Waeni, Ralf Clemens, Sue-Ann Costa Clemens, James Tuju, Charles J Sande
medRxiv 2024.01.10.24300883; doi: <https://doi.org/10.1101/2024.01.10.24300883>

[Patient engagement in research; benefits, challenges, importance, and implications](#)

Caitlyn Ivany, Tess Hudson, Patricia Schneider, Hadia Farrukh, Marilyn Swinton, Michelle Ghert
medRxiv 2023.03.28.23287870; doi: <https://doi.org/10.1101/2023.03.28.23287870> Revision

Objective Patient engagement (PE) and patient-oriented research have begun to reshape the thought process behind conducting research with the aim of maximizing the relevance of findings for patients. This study aimed to examine the perceived benefits, challenges, importance, and implications of patient engagement from the perspectives of sarcoma patient advisors and researchers.

[Migrant children participation during emergencies: A Scoping review of global challenges and opportunities](#)

Bassma Aammar, Pascale Salameh, Jose Isaias Garcia Ulerio
medRxiv 2024.01.09.24300971; doi: <https://doi.org/10.1101/2024.01.09.24300971>

Objective The aim of this scoping review is to map the existing literature regarding child participation in emergencies. Consecutively, we want to identify opportunities and challenges related to child participation in emergency response and recovery interventions for migrant or internally displaced children (IDP).

[Assessing the lack of diversity in genetics research across neurodegenerative diseases: a systematic review of the GWAS Catalog and literature](#)

Caroline Jonson, Kristin S. Levine, Julie Lake, Linnea Hertslet, Lietsel Jones, Dhairya Patel, Jeff Kim, Sara Bandres-Ciga, Nancy Terry, Ignacio F. Mata, Cornelis Blauwendraat, Andrew B. Singleton, Mike A. Nalls, Jennifer S. Yokoyama, Hampton L. Leonard
medRxiv 2024.01.08.24301007; doi: <https://doi.org/10.1101/2024.01.08.24301007>

OSF Pre-prints

<https://osf.io/preprints/discover?provider=OSF&subject=bepress%7CLife%20Sciences>

[Provider Filter: OSF Pre-prints Subject filters: Arts & Humanities; Education, Life Sciences; Medicine and Health Sciences; Social and Behavioral Sciences]

We observe increasing levels of "posting pollution" by individuals, sometimes posting 10+ items of no value. We will resume selective monitoring beginning in September.

Wellcome Open Research

<https://wellcomeopenresearch.org/browse/articles>

[Accessed 13 Jan 2024]

Selected Research

Open Letter Open Access

[Strengthening global health policies, guidance, regulations: responding to calls for public consultation by integrating diverse voices, experience and expertise](#) [version 1; peer review: awaiting peer review]

David R Curry, Sedem Adiabou, Daima Bukini, Lynn Ang, Thalia Arawi, Beate Aurich, Mariam Hassan, Fernando Lolas, Rita S Sitorus, Yeyang Su

Abstract

In this open letter, members of the Global Forum for Research Ethics and Integrity [GFREI] – an open, independent collaborative involving 80+ individuals in 30+ countries – report on and extend

arguments made during a workshop conducted at the Oxford Global Health and Bioethics International Conference (June 26–27, 2023). Ten GFREI presenters from nine countries used a case study approach to present and discuss an emerging model to integrate diverse global voices in engaging open public consultation opportunities – sometimes termed calls for input, calls for public comment, requests for information (RFIs). A key form of public consultation invites observations and ideas on, and specific edits to, draft versions of policies, guidance, regulations, and other formats under a specific deadline. Based on our experience, we posit that engagement of public consultation opportunities is a matter of transnational civic responsibility; that such engagement can add substantive value to public discourse and the realization of public good; that engaging voices and views from all global regions, and respecting and integrating diverse contributions from varying experience, expertise and forms of knowledge significantly strengthens public consultation responses; and that sustaining and extending GFREI’s independent global voice, and building its diversity and the range of disciplines represented, is worthy of robust support from the global community. Finally, we call on the ethics/bioethics community to engage these calls as an important strategy in advancing the ethical soundness of the laws, regulations, policies, guidelines presented for public consultation.

Research Article Open Access

[Improving modelling for epidemic responses: reflections from members of the UK infectious disease modelling community on their experiences during the COVID-19 pandemic](#) [version 1; peer review: awaiting peer review]

Katharine Sherratt, et al.

Abstract

Background

The COVID-19 pandemic both relied and placed significant burdens on the experts involved from research and public health sectors. The sustained high pressure of a pandemic on responders, such as healthcare workers, can lead to lasting psychological impacts including acute stress disorder, post-traumatic stress disorder, burnout, and moral injury, which can impact individual wellbeing and productivity.

* * * *

[Think Tanks](#)

Brookings [to 13 Jan 2024]

<http://www.brookings.edu/>

Research

[The pandemic inflation episode is still unwinding](#)

Louise Sheiner

January 12, 2024

[Why globalization is now in the crossfire](#)

Bruce Jones

January 11, 2024

[Social and development impact bonds by the numbers](#)

Emily Gustafsson-Wright, Elyse Painter

January 11, 2024

Center for Global Development [to 13 Jan 2024]

<https://www.cgd.ev.org/>
All Research [Selected]
No new digest content identified.

Chatham House [to 13 Jan 2024]
<https://www.chathamhouse.org/>
Selected Analysis, Comment, Events
No new digest content identified.

Council on Foreign Relations [to 13 Jan 2024]
<https://www.cfr.org/media/news-releases>
New Releases [Selected]
No new digest content identified.

CSIS [to 13 Jan 2024]
<https://www.csis.org/>
Reports [Selected]
No new digest content identified.

Kaiser Family Foundation [to 13 Jan 2024]
https://www.kff.org/search/?post_type=press-release
Newsroom
[How Has History Shaped Racial and Ethnic Health Disparities?](#)
January 11, 2024 News Release

KFF's new interactive timeline explores how history has shaped racial and ethnic health disparities and the lasting effects that persist to this day. The timeline describes major U.S. federal policies and events since the early 1800s that are linked to present-day health disparities. It also covers policies that impact health...

McKinsey Global Institute [to 13 Jan 2024]
<https://www.mckinsey.com/mgi/overview>
Latest Research
No new digest content identified.

ODI [Overseas Development Institute] [to 13 Jan 2024]
<https://odi.org/en/publications/>
Publications [Selected]
No new digest content identified.

Pew Research Center [to 13 Jan 2024]
<https://www.pewresearch.org/>
Latest Publications [Selected]
short reads | Jan 9, 2024

[U.S. centenarian population is projected to quadruple over the next 30 years](#)

The number of Americans ages 100 and older is projected to more than quadruple over the next three decades.

Rand [to 13 Jan 2024]

<https://www.rand.org/pubs.html>

Published Research [Selected]

No new digest content identified.

Urban Institute [to 13 Jan 2024]

<https://www.urban.org/publications>

[New Research Publications - Selected](#)

World Economic Forum [to 13 Jan 2024]

<https://agenda.weforum.org/press/>

Media [Selected]

News 10 Jan 2024

[Global Risks 2024: Disinformation Tops Global Risks 2024 as Environmental Threats Intensify](#)

- Digital transformation and new tech tools can provide scalable solutions to systemic challenges straining global healthcare system, new research finds.
- The newly launched Digital Healthcare Transformation Initiative will accelerate public-private collaboration around digital health, data and artificial intelligence.
- The report highlights how several critical enablers could revolutionize healthcare and counter the interconnected challenges it is facing globally.
- Read the full report [here](#).

[World Economic Forum Launches New Global Initiative to Advance Digital and AI-Driven Transformation of Healthcare Systems](#)

- Digital transformation and new tech tools can provide scalable solutions to systemic challenges straining global healthcare system, new research finds.
- The newly launched Digital Healthcare Transformation Initiative will accelerate public-private collaboration around digital health, data and artificial intelligence.
- The report highlights how several critical enablers could revolutionize healthcare and counter the interconnected challenges it is facing globally.
- Read the full report [here](#).
-

.....

.....

Public Consultations/Call for Inputs/Call for Papers

[Public consultation on antimicrobial manufacturing effluent guidance](#)

21 December 2023

Deadline: 26 January 2024.

Summary

WHO is seeking public feedback on draft "WHO Guidance on waste and wastewater management in pharmaceutical manufacturing with emphasis on antibiotic production"

Antibiotics provide great value to humanity to prevent and treat infectious disease. However, environmental emission of antibiotics during manufacturing has potential to contribute to the

emergence and spread of AMR. Therefore, there is a recognised need, stemming from a World Health Assembly resolution and the [Global Action Plan on AMR](#), for international evidence-based guidance and tools on the management of manufacturing waste containing antimicrobials to guide the target audiences of this document.

Public submitters can download the draft guidance and background documents below and provide comments in the [online feedback form](#) before 26 January 2024.

:: [WHO Guidance on waste and wastewater management in pharmaceutical manufacturing with emphasis on antibiotic production](#)

:: [Background document on derivation of PNECs for resistance selection](#)

Concept paper on the revision of the Non-clinical and Clinical Module of the influenza vaccines guideline (PDF/177.49 KB)

EMA

First published: 31/10/2023 **Consultation dates: 01/11/2023 to 30/01/2024**

Summary/Problem statement [Excerpt]

The proposed guideline will replace Guideline on influenza vaccines, non-clinical and clinical modules (EMA/CHMP/VWP/457259/2014).

...The current guideline text addresses collection of vaccine effectiveness data for approved vaccines by season. The collection of reliable data, especially brand-specific data, has proven difficult even within countries with high quality influenza disease surveillance. There is a need to rediscuss the feasibility of the current recommendations, while still acknowledging the utility of such data to detect unexpected effectiveness signals.

Overall, there is some degree of urgency to revise the guideline on non-clinical and clinical development of influenza vaccines. In particular, to add sections relevant to the development of mRNA-based influenza vaccines and to reflect on how lessons learned from the COVID-19 pandemic could be relevant to the development of influenza vaccines, including those intended only for pandemic usage.

Comments should be provided using this [EUSurvey form](#). For any technical issues, please contact the [EUSurvey Support](#)

Call for Papers: Establishing the impact of WHO's normative and standard-setting functions: a call for papers

WHO - Bull World Health Organ. 2023 Oct 1; 101(10): 618–618A. Published online 2023 Oct 1.

The deadline for submissions is 1 March 2024

Editorial

Lisa M Askie^a, Rebekah AL Thomas^a, Rok Ho Kim^a, Mubashar Sheikh^a, Jeremy Farrar^b

doi: 10.2471/BLT.23.290829 PMID: PMC10523809

Normative leadership is a core function of the World Health Organization's (WHO) mandate, as outlined in its founding principles.¹ This leadership role is realized by developing evidence-based and ethically sound guidelines as well as other normative products that guide Member States in their public health decisions and actions, and by ensuring their recommendations are implemented.² WHO exercises its capacity for normative leadership to influence the development of legal norms and health policy and practice within its Member States...

... In the past five years, WHO has initiated a major change process, driven by its current Thirteenth Global Programme of Work,⁶ the transformation agenda, and the need to respond to major global events including the coronavirus disease 2019 (COVID-19) pandemic and other crises. More recently, WHO has developed a comprehensive strategy to enhance its capacities and capabilities at country level, to ensure that its normative work drives measurable impact for all people more effectively.

Despite these initiatives, to date it is unclear whether these changes have improved WHO's credibility and impact as a normative organization. Questions remain as to how successful WHO's normative leadership role has been, how it can be further strengthened and how the impact of WHO's work in countries should be measured and rated in the future. The recent COVID-19 pandemic exposed both the strengths of and the challenges to WHO's normative leadership and global reach. While realizing the crucial role of WHO as a key directing and coordinating authority, the global health community has also witnessed the unprecedented rise of misinformation and mistrust in science.

Considering the spotlight on WHO's global normative leadership role during the pandemic,⁷ and looking to prepare for future threats such as the health effects of climate change and ongoing conflict situations, the Bulletin of the World Health Organization calls for papers to help shape and inform WHO's mandate going forward. Topics of interest include: where has WHO succeeded in its normative leadership role? In what specific areas has it successfully shaped global health, and why were these initiatives successful? Where has WHO normative guidance been less impactful? If so, why was this the case, and what lessons can be learnt to improve impact in the future? What does the future of WHO's normative function look like, particularly in the context of digital technology and artificial intelligence? What aspects of the Organization's mandate, structure, function and administration need to be further strengthened or changed?

The Bulletin welcomes contributions from all stakeholders including public health decision-makers, researchers, and civil society and community representatives. Articles that propose innovative but feasible ways by which WHO can further strengthen its normative leadership and guidance role, are encouraged.

* * * * *
* * * * *

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (CVEP) / GE2P2 Global Foundation, which is solely responsible for its content.

.....

Copyright GE2P2 Global Foundation 2023. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

.....

CVEP is a program of the [GE2P2 Global Foundation](#) whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute, and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

* * * *
* * * *